DeShazer Charles
Known title: DirectorCIK: 0001856342
DeShazer Charles's purchase track record
DeShazer Charles has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/17/2022 | CVSA | $10K | +51.6% | +81.8% | -2.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CVSA | ▼ Sell | Tax Withholding | 794 | $44K | 11/9/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,194 | $51K | 11/10/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 2,930 | $125K | 11/9/2022 | View on chart |
| CVSA | ▲ Buy | Open Market | 500 | $10K | 2/17/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 3,690 | $125K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update
Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.